Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

Documenti analoghi

• The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
  di: Jung, Hyun Ae, et al.
  Pubblicazione: (2020)
• Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
  di: Byeon, Seonggyu, et al.
  Pubblicazione: (2016)
• Are there any ethnic differences in the efficacy and safety of immune checkpoint inhibitors for treatment of lung cancer?
  di: Lee, Jiyun, et al.
  Pubblicazione: (2020)
• Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: Are They Different from Those with Common EGFR Mutations?
  di: Jung, Hyun Ae, et al.
  Pubblicazione: (2020)
• Comprehensive evaluation of the clinical utility of plasma EGFR test in non-small cell lung cancer patients with acquired resistance to first-line EGFR inhibitors
  di: Kim, Hongsik, et al.
  Pubblicazione: (2021)